BIOGEN INC. - COMMON S

Biogen to Acquire Reata Pharmaceuticals

28 Jul 2023 06:05:44 By Nasdaq GlobeNewswire

Eisai Presents Latest Analysis of Lecanemab’s Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer’s Association International Conference (AAIC) 2023

19 Jul 2023 18:30:00 By Nasdaq GlobeNewswire

FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease

06 Jul 2023 19:00:00 By Nasdaq GlobeNewswire

New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy

30 Jun 2023 15:06:00 By Nasdaq GlobeNewswire

Biogen Announces Changes to Its Board of Directors

12 Jun 2023 16:14:01 By Nasdaq GlobeNewswire

FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease

09 Jun 2023 17:45:00 By Nasdaq GlobeNewswire

Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer’s Disease

15 May 2023 18:30:00 By Nasdaq GlobeNewswire

FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS

25 Apr 2023 14:04:23 By Nasdaq GlobeNewswire

Biogen Appoints Adam Keeney as Head of Corporate Development

04 Apr 2023 06:30:00 By Nasdaq GlobeNewswire

Additional Detailed Analyses From Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals

30 Mar 2023 18:30:00 By Nasdaq GlobeNewswire

Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD™ 2023 Annual Meeting

30 Mar 2023 18:30:00 By Nasdaq GlobeNewswire

New Data Presented at AD/PD™ 2023 Show Biogen’s BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer’s Disease

29 Mar 2023 07:45:00 By Nasdaq GlobeNewswire

Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS

22 Mar 2023 19:32:40 By Nasdaq GlobeNewswire

Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA® (dimethyl fumarate) Regulatory Data and Marketing Protection

16 Mar 2023 05:30:14 By Nasdaq GlobeNewswire

Biogen Appoints Chuck Triano as Head of Investor Relations

14 Mar 2023 06:30:00 By Nasdaq GlobeNewswire

Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors

08 Mar 2023 06:30:00 By Nasdaq GlobeNewswire

FDA Accepts Eisai’s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer’s Disease

05 Mar 2023 17:30:00 By Nasdaq GlobeNewswire

Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration

27 Feb 2023 17:30:00 By Nasdaq GlobeNewswire

Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

06 Feb 2023 05:30:00 By Nasdaq GlobeNewswire

Lecanemab Receives Priority Review Status in Japan

29 Jan 2023 17:30:00 By Nasdaq GlobeNewswire